Morgan Stanley lowered the firm’s price target on Jazz Pharmaceuticals to $150 from $160 and keeps an Equal Weight rating on the shares. Compared to consensus forecasts, the firm is below on Xywav sales, in line on Xyrem sales and in line on Epidiolex sales, the analyst tells investors in a Biotechnology group preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals promotes Samantha Pearce to Chief Commercial Officer
- Jazz Pharmaceuticals price target lowered to $113 from $117 at UBS
- Jazz Pharmaceuticals’ Phase 2b trial in essential tremor doesn’t meet endpoints
- Biotech Alert: Searches spiking for these stocks today
- ‘Load Up,’ Says Goldman Sachs About These 2 Strong Buy Stocks
Questions or Comments about the article? Write to editor@tipranks.com